Cendakimab for Eosinophilic Gastritis and Duodenitis in Japanese Adults and Adolescents: Results From a Phase 3 Randomized Controlled Trial.

Authors

Yoshikazu Kinoshita, Shiro Oka, Kayoko Matsushima, Mikinori Kataoka, Tsuyoshi Sanuki, Yasuhiro Fujiwara, Katsuhiro Arai, Shuichi Midorikawa, Hirotsugu Hatai, Christina M Charriez, Sandra Zhang, Jie Li, Keigo Asano, Ichiro Nomura

Published in

The American journal of gastroenterology. Aug 28, 2026. Epub Aug 28, 2026.

Abstract

Eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD; EG/EoD) are rare, chronic inflammatory disorders lacking approved treatments.
We report a randomized, double-blind, placebo-controlled phase 3 trial evaluating cendakimab, an anti-IL-13 monoclonal antibody, in 48 Japanese patients with EG/EoD.
At week 16, cendakimab significantly reduced mean peak gastrointestinal eosinophil counts versus placebo (least squares mean difference -223.2 eosinophils/high-power field; P=0.003), with numerical improvements across symptom domains. Histologic effects were maintained at week 48 and a favorable safety profile was observed.
These findings highlight IL-13 inhibition as a potential treatment strategy for EG/EoD.

PMID:
42669462
Bibliographic data and abstract were imported from PubMed on 31 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.